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ABBREVIATION LIST
ESRD: end stage renal disease
RCC: renal cell carcinoma
EMA: epithelial membrane antigen
HMWCK: high molecular weight cytokeratin
KSC: kidney specific cadherin
CaOx: Calcium oxalate
CaOx +: Calcium oxalate pozitive
CaOx -: Calcium oxalate negative
PAS: Periodic Acid-Shiff
ACKD: Aquired Cystic Kidney Disease
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SUMMARY OF NEW RESULTS:
1. The Ph.D theses discusses renal cell carcinomas 
developing in the acquired cystic kidney disaes 
secondary to dialysis treatment.
2. The Ph.D theses describes a new phenotypic variant 
of renal cell carcinoma (called oxalate type by the 
authors) associated with intratumoral Calcium 
Oxalate depositon. The study suggests the need for a 
new classification system.
3. Immunohistochemical characterizationi of the new 
„oxalate type” renal cell carcinoma.
4. Discussion of role of the new renal cell carcinoma 
phenotype and its differentiation in the CaOx 
deposition.
5. The first case description of a carcinoasarcoma 
developed in a transplant kidney.
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INTRODUCTION:
For patients suffering from end stage renal disease 
the only therapeutic option is dialysis until a kidney becomes 
available for transplantation. The prevalence of neoplastic 
disease affecting the urinary tract in both the dialysed and the 
transplantated patient population is increased.
Acquired cystic kidney disease (ACKD) is 
characterized by small cysts randomly distributed throughout 
the renal cortex and medulla of patients with end-stage renal 
disease (ESRD) unrelated to polycystic kidney disease 
(Dunnill, etal., 1977; Grantham, 1991; Ishikawa, 1991; 
Ishikawa, et al., 1990; Matson and Cohen, 1990; Truong, et 
al., 1995). Both the prevalence and severity of ACKD increase 
with the duration of ESRD and ACKD has been reported in 
almost all patients after more than 10 years of dialysis 
(Ishikawa, 1991; Matson and Cohen, 1990).
Renal neoplasm is noted in 4.2-5.8% of ESRD 
patients, reflecting a marked increase in its incidence 
compared with the general population(Hughson, et al., 1986; 
Ishikawa, et al., 1990; Matson and Cohen, 1990; Truong, et 
al., 1995). Although these neoplasms were rarely reported in a 
shrunken kidney without cystic changes, the vast majority of 
them develop from the background of ACKD(Hughson, et al., 
1980; Ishikawa, et al., 1990; Truong, et al., 1995). The 
involvement is usually bilateral/multifocal and displays a 
spectrum of closely associated lesions including simple cysts, 
cyst lined by hyperplastic epithelium with or without atypia, 
adenoma, and renal cell carcinoma (RCC) with or without 
metastasis(Dunnill, et al., 1977; Hughson, et al., 1986). Some 
previous studies have suggested that the histologic types of 
RCCs in this context are similar to those in the general 
population but with overrepresentation of the papillary RCC 
(Dunnill, et al., 1977; Hughson, et al., 1996; Ishikawa and 
Kovács, 1993; Truong, et al., 1995). In fact, the histologic 
features of ACKD-associated RCCs are not well studied and
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many of these tumors do not fit in any categories in the current 
classification of renal neoplasms(Denton, et al., 2002; Tickoo, 
et al., 2003). One of the distinctive features of ACKD- 
associated RCCs is intratumoral deposition of calcium oxalate 
(CaOx), which was previously reported in four cases and 
briefly mentioned in a recent abstract(Denton, et al., 2002; 
Tickoo, et al., 2003). This feature, to the best of our 
knowledge, has not been described in RCCs in the general 
population. Although this finding seems unique for ACKD- 
associated renal neoplasms, many pertinent features including 
its frequency, pathogenesis and biologic implications, and the 
histologic type of the involved RCCs are not known.
For patient suffering from end stage renal disease the 
transplantation is the ulimate therapeutic solution. As a result 
of the increasing number of tranplant centers and the use of 
immunosuppressive therapy, the patients’ life expectancy is 
markedly increased and the quality of life dramatically 
improved. Besides the infection and graft versus host disease 
secondary to the immunosuppressive treatment the increased 
incidence of neoplastic diseases in post-transplant patients is a 
major concern. Geographic difference can be observed in the 
prevalence of malignancies (USA: 6%, Europe: 1-9%. 
Australia: 18,3%). After kidney transplantation Kaposi's 
sarcoma, non-Hodgkin's lymphomas, and non-melanoma skin 
cancers represents the most common secondary neoplasms 
(more than 20-fold increased than in the general population), 
the increase of genito-urinary (G-U)malignancies is also 
substantial (15-fold increase) (Kasiske, et al., 2004; Samhan, 
et al., 2005). The incidence of G-U tumors varies between 
0.64-1.67%. Since the incidence, type and other characteristics 
of prost-transplant malignancies varies in different geopraphic 
regions, many mechanism can play role in the etiology such 
as: (1) defect in immune survailance mechanism, (2) incresed 
sensitivity for oncogenic vims infection, (3) 
lymphoproliferation affecting immunologic feed back 
mechanism, (4) uremia as a predisposing condition. There are 
three distinct type of post-transplant renal neoplasms. The
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tumor can develop in the (a.) donor’s or (b.) recipient’s kidney 
prior the transplantation, which emphasises the importance of 
pretransplant renal ultrasonograph examination and 
cystoscopy. The third group is the de novo malignancies, 
which can develop in the patient’s own (90%)or in the 
tranplanted kidney (10%) (Penn, 1998). The prevalence of de 
novo renal cell carcinomas is higher (4.1-4.6%), than of the 
sporadic cases. It is important to mention the unusually high 
percentage of renal pelvis tumors (15%) among de novo 
carcinomas (Penn, 1998).
In my studies I characterized the morphological 
appearance and immunological expression profile of the renal 
neoplasias developing in ends stage kidney disease secondary 
to therapeutic modalities with special attention to those 
neoplasms with calcium oxalate deposition. Beside reviewing 
the literature I also first describe a rare type of neoplasm 
presented in a transplanted kidney.
MATERIALS AND METHODS:
I. Neoplasms developing in the native kidneys of the 
dialysis treated patients
The study features 30 end-stage renal disease 
(ESRD)-associated RCCs identified within a 13-year period, 
including eight with CaOx deposition, were analyzed. 
Pathologic and clinical features of CaOx positive (+) and 
negative (-) RCCs were evaluated and compared.
II. Neoplasm developing in renal transplant patients
The study describes a renal carcinoasarcoma 
developed in an allograft kidney and reviews neoplastic 
diseases arising in transplant patients with special attention to 
genito-urinary neoplasms.
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RESULTS:
I. Neoplasms developing in the native kidneys of the 
dialysis treated patients
The CaOx+ RCCs showed higher tendency for 
bilaterality and multifocality. Seven tumors displayed 
distinctive morphologic features characterized by tumor cells 
with ill-defined cell membrane, abundant granular 
eosinophilic cytoplasm, large nuclei, and prominent nucleoli. 
One tumor was of clear cell type. Regardless of histologic 
type, all tumors displayed a proximal tubular differentiation. 
No significant difference was noted for tumors’ stage, 
proliferation and apoptosis rate between the CaOx+ and 
CaOx- RCCs.
II. Neoplasm developing in renal transplant patients
A multifocal urothelial carcinosarcoma of a 
transplanted kidney in a 49-year-old woman is described. The 
performed immunohistochemical characterization revealed the 
CK positivity of both the epithelial and the sarcomatoid areas. 
Vimentin expression of the sarcomatoid component was also 
noted. Genomic analysis of the extracted nuclei of all the 
neoplastic cells showed uniformly XY genotype proving the 
transplant origin of the tumor. The occurence of the 
carcinosarcoma is extremly rare, our case represents the first 
published case in the english literature.
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DISCUSSION:
I. Neoplasms developing in the native kidneys of the 
dialysis treated patients
This comprehensive evaluation of CaOx+ RCCs in 
ESRD patients shows that they are not rare and indeed 
accounted for 8/30 (27%) of all RCCs developing from this 
background. This high incidence is somewhat surprising 
because only 19 CaOx + RCCs were previously reported (Dry 
and Renshaw, 1998; Rioux-Leclercq and Epstein, 2003) and 
this type of RCC was not mentioned in any large studies on 
ESRD-associated renal neoplasms (Denton, et al., 2002; 
Doublet, et al., 1997; Dunnill, et al., 1977; Hughson, et al., 
1986; Hughson, et al., 1980; Hughson, et al., 1996; Ikeda, et 
al., 2002; Ishikawa, et al., 1990; MacDougall, et al., 1987; 
Miller, et al., 1989; Takebayashi, et al., 2000; Truong, et al., 
1995) Since CaOx crystals are colorless but highly visible 
under polarized light in the hematoxylin-eosin stain and were 
dissolved during the periodic acid-Schiff or Mason’s 
trichrome stains, which are frequently used to evaluate ESRD- 
associated renal parenchyma changes, they may be overlooked 
unless the deposition is extensive or polarized light is 
routinely used. Although the high incidence in our study may 
be related to the fact that CaOx was specifically sought for in 
all RCCs, extensive deposition involving more than 75% of 
tumor areas were noted in 4/8 (50%) of these tumors. A recent 
abstract documented that 15 out of 43 (35%) RCCs in ESRD 
patients contain CaOx, supporting our observation that these 
tumors are not rare (Tickoo, et al., 2003).
Our study together with previous reports (Dry and 
Renshaw, 1998; Rioux-Leclercq and Epstein, 2003; Tickoo, et 
al., 2003) indicates that intra-tumoral CaOx deposition is a 
unique features of ESRD-associated renal neoplasms 
including RCCs, since, to the best of our knowledge, it has 
never been described in renal neoplasms in the general
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population and, indeed, was not observed in any of the 346 
RCCs unrelated to ESRD during the studied period. Previous 
studies by Dry et al, Rioux-Leclerq et al, and Tickoo el al 
suggested that intra-tumoral CaOx deposition is associated 
with a distinctive morphologic profile (Dry and Renshaw, 
1998; Rioux-Leclercq and Epstein, 2003; Tickoo, et al., 2003). 
The current study confirms and expands this observation, i.e., 
this profile is observed in almost all RCCs with CaOx 
deposition but only rarely seen in RCCs without it. 
Furthermore, this profile does not fit neatly into the current 
histological classification of renal tumors (Storkel, et al.,
1997).
Almost all CaOx+ RCCs were composed entirely or 
almost entirely of tumor cells with cuboidal abundant 
eosinophilic granular cytoplasm, focal but prominent 
cytoplasmic vacuolization, ill defined cell membrane, and a 
Furhman’s nuclear grade 3. These tumors, however, have 
diverse growth patterns including predominantly papillary, 
tubulopapillary, or solid/cribriform types. Although the 
amount of intra-tumoral CaOx is variable, the deposition is 
extensive and accounts for more than 75% of tumor areas in at 
least 50% of our cases. Indeed, tumor calcification was 
obvious on imaging studies of two of these cases. The CaOx 
deposition was not associated with any distinctive tissue 
reaction such as necrosis, fibrosis or inflammation only one 
case showed multinucleated giant cell reaction. This 
morphologic profile correlates well with intra-tumoral CaOx 
since it is noted in seven out of eight CaOx+ RCCs in the 
current study, all five previously reported CaOx+ RCCs, and 
all 15 CaOx+ RCCs in a recent abstract that included 43 
ESRD-associated RCCs (Dry and Renshaw, 1998; Rioux- 
Leclercq and Epstein, 2003; Tickoo, et al., 2003). On the other 
hand, this morphologic profile was found in only 1/18 CaOx- 
RCCs in the current study and none of the 28 CaOx- RCCs in 
another study (Dry and Renshaw, 1998; Rioux-Leclercq and 
Epstein, 2003; Tickoo, et al., 2003). This phenotype, however, 
is not pathognomic for intra-tumoral CaOx, since one RCC
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with extensive CaOx deposition in our study displays typical 
clear cell features.
The biologic significance of CaOx+ RCC as a 
distinctive subset of ESRD-associated RCC is not clear. 
Although bilaterality and multifocality is well known for 
ESRD-associated RCCs (Ishikawa, et al., 1990; Matson and 
Cohen, 1990; Truong, et al., 1995), we found that these 
features are significantly more frequent for the CaOx+ RCCs 
than for its CaOx- counterpart (40 vs. 0% for bilaterality and 
57 r.v11% for multifocality in the current study. This 
observation suggests that CaOx deposition, which is known to 
be quite frequent and often extensive in kidneys with ESRD, 
may promote tumor development or, alternatively, the genetic 
changes that predispose to CaOx deposition also promote 
malignant transformation.
The durations from dialysis to RCCs in our cases 
were 8-11 years (mean 9.2 years). This is significantly longer 
than the mean duration of 5 year reported by Houghson et al 
for ACKD-associated RCCs (Hughson, et al., 1986; Hughson, 
et al., 1980; Hughson, et al., 1996), regardless of histologic 
subtype. This difference suggests that the increased bilaterality 
and multifocality of CaOx+ RCCs may be at least in part 
related to the duration of dialysis. On the other hand, we have 
noted that CaOx deposition was always significantly more in 
CaOx+ RCCs than in the adjacent kidney tissue but the renal 
tissue deposition of CaOx was not different between those 
with CaOx+ RCCs and those with CaOx- RCC. These 
observations suggest that CaOx deposition within the tumor 
itself may be related to their behavior. Although the majority 
of ESRD-associated RCCs develop from the background of 
ACKD, those without associated ACKD have been noted and 
they account for 9-25% of all ESRD-associated RCCs 
(Denton, et al., 2002; Tickoo, et al., 2003). In contrast, all 
CaOx+ RCCs (eight in the current study, five previously 
reported, and 15 in a recent abstract) are associated with 
ACKD (Dry and Renshaw, 1998; Rioux-Leclercq and Epstein, 
2003; Tickoo, et al., 2003). These observations suggest some
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pathogenetic links among tumor bilaterality/ multifocality, 
renal cyst fonnation, renal parenchymal CaOx deposition, and 
intra-tumoral CaOx deposition. Regardless of the pathogenetic 
implication, our findings imply that the diagnosis of CaOx+ 
RCC should entail appropriate clinical follow-up for 
progressive renal cystic change and renal tumors of the 
contralateral kidneys.
Why CaOx is deposited in only some ESRD- 
associated RCCs, but not RCC in general, is not clear. Our 
study suggests at least two responsible factors, i.e., increased 
serum level of oxalate and a specific cell phenotype that can 
promote oxalate deposition. Since kidney is the only organ 
through which oxalate is eliminated, increased serum level of 
oxalate is expected along with chronic renal failure regardless 
of etiology (Salyer and Keren, 1973). It is estimated that 
serum oxalate level starts to increase when glomerular 
filtration rate is less than 25ml/ minute (Morgan, et al., 1987) 
Since dialysis can only remove a fraction of the daily oxalate 
intake, this positive balance is even worse in ESRD patients 
and the serum level as well as the body burden of oxalate in 
these patients is progressively increased (Hoppe, et al., 1999; 
Worcester, et al., 1994). In physiologic condition, oxalate is 
freely filtered through the glomerular capillaries and 
undergoes bi-directional transport through the proximal 
tubules resulting in increased concentration in the tubular 
lumen, whereas other portions of the nephron do not 
participate in handling of oxalate (Hatch and Freel, 2003).
Our study indicates that the immunoprofile of the CaOx+ 
RCCs is quite uniform with pronounced expression of markers 
for proximal tubular differentiation including the RCC marker 
and CD 10 and absent or weak expression of the markers for 
distal portion of the nephron such as KSP, HMWCK, or EMA. 
These observations suggest that proximal tubular 
differentiation may play a crucial role in promoting intra- 
tumoral CaOx deposition. We also propose that it is the 
proximal differentiation, rather than light microscopic 
phenotype, that is important for CaOx deposition since the
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only CaOx+ clear cell RCC known to us also displayed strong 
proximal differentiation, like those with the “oxalate” 
phenotype. In contrast, all CaOx- RCCs in our study showed 
predominantly distal nephron differentiation, even though 
several of them are of clear cell or papillary types, which are 
known to derive from proximal tubules in the sporadic RCC 
(Kim and Kim, 2002; McGregor, et al., 2001). Our study also 
demonstrated that CaOx may deposit in adenomas, cysts, or 
dilated tubules, but only in those with an immunoprofile of 
proximal tubular differentiation, further implicating its role in 
renal CaOx deposition. Additional factors may be involved in 
CaOx deposition. Several molecules are known to inhibit 
CaOx crystal formation in physiologic condition, including 
nerphrocalcin, osteonectin, mannan-binding lectin associated 
plasma protein, and FK506-binding protein, some of which 
are immunolocalized to renal proximal tubules (Ikeda, et al., 
2002). It is possible that lower levels of these molecules may 
promote CaOx deposition. Although this hypothesis has not 
been tested, at least one of these molecules, i.e., nephrocalcin 
was identified in RCCs and shown to decrease in ESRD- 
associated RCCs (Michaels, et al., 1998). Whether this 
decrease is limited to the CaOx+ tumors in this context is not 
known.
CaOx is known to induce significant changes in 
cultured tubular cells. It may be mitogenic at lower 
concentration but may cause cell necrosis or apoptosis at 
higher concentration (Koul, et al., 1994; Scheid, et al., 1996). 
CaOx can induce intracellular formation of reactive oxygen 
species and inhibit several cytosolic enzymes, which may 
account for its cytotoxic effects (Koul, et al., 1994; Scheid, et 
al., 1996). CaOx is the major factor in renal tissue injury in 
renal oxalosis, a condition characterized by renal tissue 
deposition of CaOx. In the context of ESRD, CaOx was 
thought to promote cyst and tumor formation through both 
mechanical obstructions of renal tubules and regulation of 
tubular cell cycles révén (Hughson, et al., 1986; Ishikawa, 
1991; Lieske, et al., 1992; Truong, et al., 1995). What impact
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that intra-tumoral CaOx has on tumor cells, however, is not 
clear. In the current study, we did not observe in the majority 
of cases (7/8) any specific tissue reaction in the tumor tissue 
around the CaOx crystals, only one case showed 
multinucleated giant cell reaction. Furthermore, the rates of 
tumor cell proliferation and apoptosis of the CaOx+ RCCs as 
detennined by Ki 67, a specific cell proliferation marker, and 
in situ end-labeling of fragmented DNA, respectively, were 
widely variable among CaOx+ RCCs but were not 
significantly different from those of CaOx- RCCs. These 
features suggest that CaOx deposition may not have any 
significant impact on tumor cell kinetics.
The behavior of ESRD-associated RCCs, especially 
those develop in the context of ACKD, is well known. 
Compared to sporadic RCCs, these tumors are usually of 
lower grades, lower stages, with a lower metastatic rate and a 
better survival (Truong, et al., 1995). However, the behavior 
of different histologic subtypes of RCCs, including the CaOx+ 
ones, within the broad category of ESRD-associated RCC is 
not known. Although the CaOx+ RCCs displayed a higher 
nuclear grade than the CaOx- RCCs, this study suggests that in 
the context of ESRD, they have the same behavior since no 
significant difference was noted in these two groups for the 
tumors’ stage, proliferation rate, and apoptotic rate, and the 
patients’ survival. Nevertheless, this suggestion needs to be 
corroborated in further studies with more cases
II. Neoplasm developing in renal transplant patients
The transplantation provides a better quality of life 
for the patients if compared to dialysis. The risk of neoplastic 
diseases is increased after transplantation due to the 
iimnunosuppressive therapy. This increased risk, though it is 
still present, is less prominent if we compare it to the dialysis 
treated patients.
After transplantaton the majority of renal neoplastic 
proliferations develop in the native kidney, a small proportion
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of post-transplant malignancies can also arise in the donor 
organs. The majority of these neoplasms are renal cell 
carcinoma, but the relative proportion urothelial carcinoma of 
the renal pelvis is increased (15%) (Penn, 1995)compared to 
the sporadic cases (8-10 %). Of course, most of these tumors 
are urothelial carcinoma, but previously in transplanted kidney 
not reported rare types of cancer can occur in this location.
SUMMARY
Renal neoplasm is noted in 4.2-5.8% of ESRD 
patients, reflecting a marked increase in its incidence 
compared with the general population. In summary, CaOx+ 
RCCs accounts for a significant portion of all ESRD- 
associated RCCs. Almost all of these RCCs display a 
distinctive morphologic profile, which does not fit the current 
histologic classification of RCC. These RCCs seems to have 
the same relatively good prognosis shared by other ESRD- 
associated RCCs
The transplantation provides a better quality of life 
for the patients if compared to dialysis. The risk of neoplastic 
diseases is increased after transplantation due to the 
immunosuppressive therapy.
Both dialyzed and transplanted patients should be 
monitored for the development of malignancy in native 
kidneys, the allograft and elsewhere.
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